Abstract
Myostatin is a negative regulator of muscle mass. Important advances in our understanding of thecomplex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Herewe present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Keywords: Myostatin, Muscle, Adipose tissue, Rhabdomyosarcoma, Myostatin antagonism, Myostatin processing and signaling, therapeutic approaches
Mini-Reviews in Medicinal Chemistry
Title: Myostatin: Biology and Clinical Relevance
Volume: 6 Issue: 7
Author(s): Gilles Carnac, Stephanie Ricaud, Barbara Vernus and Anne Bonnieu
Affiliation:
Keywords: Myostatin, Muscle, Adipose tissue, Rhabdomyosarcoma, Myostatin antagonism, Myostatin processing and signaling, therapeutic approaches
Abstract: Myostatin is a negative regulator of muscle mass. Important advances in our understanding of thecomplex biology of this factor have revealed the therapeutic potential of antagonizing the myostatin pathway. Herewe present the rationale for evaluating anti-myostatin therapies in human muscle-wasting disorders.
Export Options
About this article
Cite this article as:
Carnac Gilles, Ricaud Stephanie, Vernus Barbara and Bonnieu Anne, Myostatin: Biology and Clinical Relevance, Mini-Reviews in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/138955706777698642
DOI https://dx.doi.org/10.2174/138955706777698642 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Current Pharmaceutical Design IP6 in Cancer Therapy: Past, Present and Future
Current Cancer Therapy Reviews The Urokinase Receptor Interactome
Current Pharmaceutical Design Gene Replacement Therapies for Duchenne Muscular Dystrophy Using Adeno-Associated Viral Vectors
Current Gene Therapy Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Development of 5-Fluorouracil Derivatives as Anticancer Agents
Current Medicinal Chemistry PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Clinicopathological Characteristics of Chinese Colorectal Cancer Patients under 30 Years of Age: Implication in Diagnosis and Therapy
Current Cancer Drug Targets The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews